SANOFISanofi India Limited
Pharma · Drug Manufacturers - General · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company offers pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, anti-infectives, and central nervous system under the Lantus, Toujeo, Soliqua, Clexane, Amaryl, Cardace, Lasix, Lasilactone, Glimepiride, Cetapin, Targocid, Frisium, Targocio, Combiflam, DePura, Allegra, Baralgan, BUSCOGAST, Dulcoflex, Enterogermina, Novalgin, and Avil brands through independent distributors. It also exports its products. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited operates as a subsidiary of Hoechst GmbH.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
The picture
- • Profit growth: 20.1% YoY
- • ROE: 40.3%
- • ROCE: 59.2%
- • Volume: 1.6x 20-day average
- • Volatility: 19% annualized
- • Liquidity: ₹3.9 cr avg turnover
- • RSI Oversold Reversal signal (setup quality 65%)
Bull case
- • Profit growth: 20.1% YoY
- • ROE: 40.3%
- • ROCE: 59.2%
- • Volume: 1.6x 20-day average
Bear case
- • Revenue growth: 7.7% YoY
- • RSI: 35
- • MACD: bearish
- • 1-month return: -8.9%
Key risks
- • Momentum is fading versus the broader market
- • Revenue growth: 7.7% YoY
- • RSI: 35
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹64.49). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.